Developer docs
API playgroundTry for free, no card

Search company profiles

Baysient

Full company profile

uuid0033rgn

Namestring
Baysient
Legal namestring
Baysient LLC
Websiteurl
baysient.com
Company typeenum
Private
Founded yearstring
-
Descriptiontext

Baysient LLC is a privately held US software company headquartered in Fort Myers, Florida, that builds cloud-based precision dosing software for anti-inflammatory monoclonal antibody (MAb) therapies used in conditions such as inflammatory bowel disease (IBD). Its core product, iDose, applies a proprietary "Compuceutical" methodology — combining Bayesian pharmacokinetic models with routine lab results (drug levels, anti-drug antibodies) and patient demographic data — to help physicians calculate individualized doses targeted to a specific trough level. The platform is FDA-regulated and protected by patents covering iDose and the T3 (Time to Target) module; a companion module, Tuminimize, supports dose optimization. The latest release, iDose GEN7.0 (February 2026), expanded coverage to 17 inflammatory disease indications and added predictive analytics tools.

Baysient sells on a subscription basis to two primary customer segments: enterprise healthcare organizations (sold via direct/enterprise sales motions) and individual physicians (served through a demo-driven self-service flow). Federal law requires the software to be used by or under the supervision of a healthcare professional, and pricing is quote-based and not publicly disclosed. The company has 11-50 employees, no disclosed institutional funding or parent company, and a named team of seven led by PhD-level Chief Science Officer Diane R. Mould. Distribution is currently domestic (United States), and the company relies on a digital-first marketing approach (website, blog, video, LinkedIn/Twitter/Facebook) to drive physician education and demo requests.

The business model is best characterized as a niche, regulated clinical SaaS targeting a high-acuity but narrow prescriber base (specialists managing anti-TNF therapy). Its revenue mechanics depend on subscription renewals from physicians and healthcare organizations, with growth levers tied to indication expansion, regulatory clearance for new biologics, and penetration into additional inflammatory disease specialties.

Short descriptiontext

Baysient LLC is a US-based clinical SaaS company that sells FDA-regulated, cloud-based precision dosing software (iDose) using Bayesian pharmacokinetic models to help physicians individualize anti-inflammatory monoclonal antibody therapy for patients with inflammatory diseases such as IBD.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
51–100
akta.pro rankint
HeadquartersFort Myers, United States
HQ citystring
Fort Myers
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Keyword5 values
precision dosing software, therapeutic drug monitoring, Bayesian dosing platform, biologic therapy optimization, clinical decision support
Industry1 code
PRIMARYHLACANAH
Therapeutic Companion Apps (Drug-Device-Digital Combination)
Healthcare & Life Sciences/Digital Health & Health IT/Digital Therapeutics (DTx) & Software as a Medical Device (SaMD)
NAICS code2 codes
  • Computer Systems Design and Related Services54151
  • Health Care and Social Assistance62
SIC code2 codes
  • Services-Prepackaged Software7372
  • Services-Health Services8000
Product category
Precision Dosing Software
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model1 record
1Software Subscription (iDose Platform)
TypeSubscription Recurring
Description

Baysient appears to operate on a subscription basis for healthcare organizations and physicians accessing the iDose precision dosing platform. The software is regulated by the FDA and provided as a cloud-based service requiring individual account provisioning under healthcare professional supervision.

baysient.net
Marketing channels4 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels2 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Personnel, Technology or R&D, Operations, Marketing or Sales, Infrastructure
Pricing details1 tier
1Enterprise and individual physician subscription tiers
ModelSubscriptionBilling cadenceAnnual
Notes

Quote-based / Not publicly disclosed. Individualized pricing for healthcare organizations and physician practices.

baysient.net
GTM typeB2B
B2B
Offering typeSoftware
Software
Brand1 of 3 records shown
1iDose®
Description

Integrative, cloud-based software that facilitates individualized dosing of all marketed MAbs used to treat inflammatory diseases.

baysient.net
+2 more records
Core offering1 text field

Baysient develops and sells iDose®, a cloud-based, FDA-regulated software platform that uses Bayesian models, routine lab results, and demographic information to help physicians calculate individualized doses of anti-inflammatory monoclonal antibodies (MAbs) to specific target trough levels for patients with inflammatory diseases such as IBD. The core iDose platform is complemented by companion modules Tuminimize™ (dosing protocol optimization) and T3® Time to Target (time-to-target trajectory planning), with subscriptions sold to healthcare organizations and individual physicians.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 value
  • Up to half of patients on anti-TNF therapy experience secondary loss of response, much of which is pharmacokinetic and addressable through precision dosing
Product overview1 text field

Baysient offers a unified precision dosing platform built around its core product iDose®, supported by companion modules Tuminimize™ and T3® (T3 Time to Target®). The platform utilizes a pioneering Compuceutical approach combining Bayesian models, routine lab results, and demographic information to enable individualized dosing of anti-inflammatory monoclonal antibodies. The platform has expanded to cover 17 inflammatory disease indications and is FDA-regulated. iDose® serves as the primary integrative software, while Tuminimize™ optimizes dosing protocols and T3® addresses time-to-target treatment planning.

Product and service2 records
1iDose®
CategoryPrecision dosing software
Description

Integrative, cloud-based, FDA-regulated software that uses Bayesian models, routine lab results, and demographic information to facilitate individualized dosing of all marketed anti-inflammatory monoclonal antibodies (MAbs) used to treat a wide range of inflammatory diseases. Used by physicians and healthcare organizations under medical supervision.

2Tuminimize™
Scale indicator1 record

Each record includes

Type, Value, Description, Source

Recent move3 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight4 records

Each record includes

Type, Description

Peers10 records
1Prometheus Biosciences
TypeBroad incumbent
Description

Prometheus (acquired by AbbVie in 2023) pioneered companion-diagnostic / TDM-style testing for IBD biologics. Although now part of a large pharma, it is the historical reference point in IBD therapeutic drug monitoring and a benchmark for the value of precision-dosing data in inflammatory bowel disease.

2Oracle Health (formerly Cerner)
TypeOthers
Description

Oracle Health provides large-scale EHR and population-health infrastructure across U.S. hospitals and IDNs. As with Epic, it is not a direct competitor in Bayesian dosing but represents an adjacent health-IT incumbent that could integrate or displace point solutions like Baysient at the enterprise tier.

TypeBroad incumbent
Description

Quest Diagnostics provides routine and specialty TDM testing services, including biologic level and anti-drug antibody assays relevant to anti-TNF therapy. As a scaled clinical lab it is a comparable TDM data source and a potential partner or competitor to Baysient.

TypeEmerging player
Description

Satisfai Health builds AI tools for gastroenterologists with a focus on IBD and GI-related clinical workflows. It is comparable to Baysient as a digital-health vendor aiming to embed evidence-based software into the IBD treatment pathway.

TypeDirect peer
Description

DoseMe (acquired by Tabula Rasa HealthCare / now part of CareVention HealthCare) offers a Bayesian model-based, cloud precision-dosing SaaS for clinicians. It is the most directly comparable competitor to Baysient's iDose platform in technology architecture, dosing methodology, and subscription go-to-market.

TypeEmerging player
Description

Iterative Health is an AI/SaaS company focused on gastroenterology, including IBD-related clinical decision support and endoscopy workflows. It targets the same IBD-prescribing physician base Baysient serves, but addresses different pain points (imaging/AI) rather than dosing.

TypeBroad incumbent
Description

ARUP is a large academic reference laboratory that offers specialized TDM and biologic monitoring assays used by gastroenterologists and rheumatologists. It functions as a leading TDM competitor / data source across the same anti-TNF monitoring niche as Baysient.

TypeOthers
Description

Epic is the dominant EHR vendor for large U.S. health systems and a frequent channel for third-party clinical-decision-support tools. It does not directly dose biologics today but is the obvious embedding point that could host, replace, or block third-party dosing apps like iDose.

TypeBroad incumbent
Description

Labcorp operates a broad reference-laboratory network including therapeutic-drug-monitoring assays used by IBD and rheumatology prescribers. It represents the incumbent lab-based TDM channel that Baysient's software-anchored model is partially substituting.

TypeEmerging player
Description

Virgo provides cloud-based endoscopy video capture and AI analytics for GI practices. It overlaps with Baysient's gastroenterology buyer segment and represents an adjacent point-of-care SaaS play in IBD-relevant specialty care.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks5 records

Each record includes

Headline, Details, Source

Key highlights6 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment2 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI capability3 records

Each record includes

Type, Description, Source

AI maturity
App detail

Has app

Feature3 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles1 record

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Baysient

Precision Dosing Softwarebaysient.com

Baysient LLC is a US-based clinical SaaS company that sells FDA-regulated, cloud-based precision dosing software (iDose) using Bayesian pharmacokinetic models to help physicians individualize anti-inflammatory monoclonal antibody therapy for patients with inflammatory diseases such as IBD.

What Baysient does

Baysient LLC is a privately held US software company headquartered in Fort Myers, Florida, that builds cloud-based precision dosing software for anti-inflammatory monoclonal antibody (MAb) therapies used in conditions such as inflammatory bowel disease (IBD). Its core product, iDose, applies a proprietary "Compuceutical" methodology — combining Bayesian pharmacokinetic models with routine lab results (drug levels, anti-drug antibodies) and patient demographic data — to help physicians calculate individualized doses targeted to a specific trough level. The platform is FDA-regulated and protected by patents covering iDose and the T3 (Time to Target) module; a companion module, Tuminimize, supports dose optimization. The latest release, iDose GEN7.0 (February 2026), expanded coverage to 17 inflammatory disease indications and added predictive analytics tools.

Baysient sells on a subscription basis to two primary customer segments: enterprise healthcare organizations (sold via direct/enterprise sales motions) and individual physicians (served through a demo-driven self-service flow). Federal law requires the software to be used by or under the supervision of a healthcare professional, and pricing is quote-based and not publicly disclosed. The company has 11-50 employees, no disclosed institutional funding or parent company, and a named team of seven led by PhD-level Chief Science Officer Diane R. Mould. Distribution is currently domestic (United States), and the company relies on a digital-first marketing approach (website, blog, video, LinkedIn/Twitter/Facebook) to drive physician education and demo requests.

The business model is best characterized as a niche, regulated clinical SaaS targeting a high-acuity but narrow prescriber base (specialists managing anti-TNF therapy). Its revenue mechanics depend on subscription renewals from physicians and healthcare organizations, with growth levers tied to indication expansion, regulatory clearance for new biologics, and penetration into additional inflammatory disease specialties.

Baysient firmographics

Firmographics
Name
Baysient
Legal name
Baysient LLC
Website
https://baysient.com
Company type
Private
Operating status
Operating
Headcount range
51–100 employees
Short description
Baysient LLC is a US-based clinical SaaS company that sells FDA-regulated, cloud-based precision dosing software (iDose) using Bayesian pharmacokinetic models to help physicians individualize anti-inflammatory monoclonal antibody therapy for patients with inflammatory diseases such as IBD.
Ownership category
akta.pro rank

Baysient industry classification

Industry
Product category
Precision Dosing Software
NAICS
Computer Systems Design and Related Services (54151), Health Care and Social Assistance (62)
SIC
Services-Prepackaged Software (7372), Services-Health Services (8000)
akta.pro industry
PRIMARYHLACANAH
Therapeutic Companion Apps (Drug-Device-Digital Combination)
Healthcare & Life Sciences/Digital Health & Health IT/Digital Therapeutics (DTx) & Software as a Medical Device (SaMD)

Keywords

  • Precision dosing software
  • Therapeutic drug monitoring
  • Bayesian dosing platform
  • Biologic therapy optimization
  • Clinical decision support

Where Baysient is headquartered

Location

Headquarters

HQ city
Fort Myers
HQ country
United States
HQ region
North America

Markets served

Baysient business model

Business model
GTM type
B2B
Offering type
Software
Cost components
Personnel, Technology or R&D, Operations, Marketing or Sales, Infrastructure

Revenue model

  1. Software Subscription (iDose Platform): Baysient appears to operate on a subscription basis for healthcare organizations and physicians accessing the iDose precision dosing platform. The software is regulated by the FDA and provided as a cloud-based service requiring individual account provisioning under healthcare professional supervision.

Pricing tiers

ModelBillingPrice
SubscriptionAnnualEnterprise and individual physician subscription tiers

Go-to-market motion1 record

Distribution channels2 records

Marketing channels4 records

Baysient product offering

Product offering

Core offering

Baysient develops and sells iDose®, a cloud-based, FDA-regulated software platform that uses Bayesian models, routine lab results, and demographic information to help physicians calculate individualized doses of anti-inflammatory monoclonal antibodies (MAbs) to specific target trough levels for patients with inflammatory diseases such as IBD. The core iDose platform is complemented by companion modules Tuminimize™ (dosing protocol optimization) and T3® Time to Target (time-to-target trajectory planning), with subscriptions sold to healthcare organizations and individual physicians.

Product overview

Baysient offers a unified precision dosing platform built around its core product iDose®, supported by companion modules Tuminimize™ and T3® (T3 Time to Target®). The platform utilizes a pioneering Compuceutical approach combining Bayesian models, routine lab results, and demographic information to enable individualized dosing of anti-inflammatory monoclonal antibodies. The platform has expanded to cover 17 inflammatory disease indications and is FDA-regulated. iDose® serves as the primary integrative software, while Tuminimize™ optimizes dosing protocols and T3® addresses time-to-target treatment planning.

Differentiator

Problem solved

Functional benefit

Brands

  • iDose®: Integrative, cloud-based software that facilitates individualized dosing of all marketed MAbs used to treat inflammatory diseases.
  • Tuminimize™
  • T3®

Products and services

  • iDose® Integrative, cloud-based, FDA-regulated software that uses Bayesian models, routine lab results, and demographic information to facilitate individualized dosing of all marketed anti-inflammatory monoclonal antibodies (MAbs) used to treat a wide range of inflammatory diseases. Used by physicians and healthcare organizations under medical supervision.
  • Tuminimize™

Quantifiable outcome

  • Up to half of patients on anti-TNF therapy experience secondary loss of response, much of which is pharmacokinetic and addressable through precision dosing

Companies that use Baysient

Customer profile

Segments2 records

Ideal customer profiles2 records

Baysient technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

AI capability3 records

Feature3 records

Baysient partnerships and signals

Strategic signal

Scale indicators1 record

Recent moves3 records

Expansion highlights4 records

Baysient competitors and assessment

Company assessment

Broad incumbents

  • Prometheus Biosciences: Prometheus (acquired by AbbVie in 2023) pioneered companion-diagnostic / TDM-style testing for IBD biologics. Although now part of a large pharma, it is the historical reference point in IBD therapeutic drug monitoring and a benchmark for the value of precision-dosing data in inflammatory bowel disease.
  • Quest Diagnostics: Quest Diagnostics provides routine and specialty TDM testing services, including biologic level and anti-drug antibody assays relevant to anti-TNF therapy. As a scaled clinical lab it is a comparable TDM data source and a potential partner or competitor to Baysient.
  • ARUP Laboratories: ARUP is a large academic reference laboratory that offers specialized TDM and biologic monitoring assays used by gastroenterologists and rheumatologists. It functions as a leading TDM competitor / data source across the same anti-TNF monitoring niche as Baysient.
  • Labcorp Drug Development / Labcorp Diagnostics: Labcorp operates a broad reference-laboratory network including therapeutic-drug-monitoring assays used by IBD and rheumatology prescribers. It represents the incumbent lab-based TDM channel that Baysient's software-anchored model is partially substituting.

Others

  • Oracle Health (formerly Cerner): Oracle Health provides large-scale EHR and population-health infrastructure across U.S. hospitals and IDNs. As with Epic, it is not a direct competitor in Bayesian dosing but represents an adjacent health-IT incumbent that could integrate or displace point solutions like Baysient at the enterprise tier.
  • Epic Systems: Epic is the dominant EHR vendor for large U.S. health systems and a frequent channel for third-party clinical-decision-support tools. It does not directly dose biologics today but is the obvious embedding point that could host, replace, or block third-party dosing apps like iDose.

Emerging players

  • Satisfai Health: Satisfai Health builds AI tools for gastroenterologists with a focus on IBD and GI-related clinical workflows. It is comparable to Baysient as a digital-health vendor aiming to embed evidence-based software into the IBD treatment pathway.
  • Iterative Health: Iterative Health is an AI/SaaS company focused on gastroenterology, including IBD-related clinical decision support and endoscopy workflows. It targets the same IBD-prescribing physician base Baysient serves, but addresses different pain points (imaging/AI) rather than dosing.
  • Virgo Surgical Solutions: Virgo provides cloud-based endoscopy video capture and AI analytics for GI practices. It overlaps with Baysient's gastroenterology buyer segment and represents an adjacent point-of-care SaaS play in IBD-relevant specialty care.

Direct peers

  • DoseMe: DoseMe (acquired by Tabula Rasa HealthCare / now part of CareVention HealthCare) offers a Bayesian model-based, cloud precision-dosing SaaS for clinicians. It is the most directly comparable competitor to Baysient's iDose platform in technology architecture, dosing methodology, and subscription go-to-market.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks5 records

Key highlights6 records

Customer concentration

Baysient social profiles

Digital presence

Baysient financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Baysient leadership team

Management profile

Number of profiles

Profiles1 record

Baysient funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Baysient M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Baysient

What does Baysient do?

Baysient develops and sells iDose®, a cloud-based, FDA-regulated software platform that uses Bayesian models, routine lab results, and demographic information to help physicians calculate individualized doses of anti-inflammatory monoclonal antibodies (MAbs) to specific target trough levels for patients with inflammatory diseases such as IBD. The core iDose platform is complemented by companion modules Tuminimize™ (dosing protocol optimization) and T3® Time to Target (time-to-target trajectory planning), with subscriptions sold to healthcare organizations and individual physicians.

Is Baysient a public or private company?

Baysient is a private company. It is classified as founder individual operated bootstrapped and is currently operating.

When was Baysient founded?

Baysient was founded in -1. It employs 51 to 100 people.

Where is Baysient based?

Baysient is headquartered in Fort Myers, United States, in the North America region.

How does Baysient make money?

One revenue line is on record: software Subscription (iDose Platform).

Who are Baysient's main competitors?

Broad incumbents on record are Prometheus Biosciences, Quest Diagnostics, ARUP Laboratories and Labcorp Drug Development / Labcorp Diagnostics. Others are Oracle Health (formerly Cerner) and Epic Systems. Emerging players are Satisfai Health, Iterative Health and Virgo Surgical Solutions. DoseMe is listed as a direct peer.

Does Baysient have an API?

No public API is recorded for Baysient.

What industry is Baysient in?

Baysient's product category is Precision Dosing Software. Its primary akta.pro industry code is HLACANAH, Therapeutic Companion Apps (Drug-Device-Digital Combination). Its NAICS code is 54151 and its SIC code is 7372.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
PR NewswireBaysient Launches iDose® GEN7.0, Expanding Precision Dosing Platform to 16 Inflammatory Disease IndicationsBaysient announced the commercial launch of iDose® GEN7.0, expanding its FDA-regulated precision dosing decision support platform from two to 17 inflammatory disease indications across gastroenterology, rheumatology, dermatology, and pulmonology specialties. The new version introduces three predictive clinical tools that assess anti-drug-antibody occurrence probability, CRP normalization probability, and mucosal healing probability at the point of care. The platform also delivers enhanced EHR/EMR integration capabilities to streamline adoption by healthcare providers optimizing biologic therapy dosing.PR NewswireCOVID-19 Infection Shown to Significantly Increase Drug Clearance of Therapeutic Monoclonal AntibodiesBaysient LLC reported that COVID-19 infection significantly increases drug clearance of therapeutic monoclonal antibodies (mAbs) such as Infliximab by 50-77%, resulting in shorter drug half-life and subtherapeutic levels that risk treatment failure and anti-drug antibody formation. The company recommends physicians implement therapeutic drug monitoring (TDM) using their T3 web-based application to adjust doses for patients who test positive for COVID-19, particularly those being treated for inflammatory conditions. Baysient's T3 software currently supports monitoring for IV infliximab, SC infliximab, adalimumab, and vedolizumab.PR NewswireBaysient Launches Digital TDM App for Fast, Personalized Infliximab DosingBaysient LLC announced the release of T3 Time To Target, a web-based application for precision dosing of Infliximab, using patient clinical characteristics and measured trough concentrations to determine drug half-life and dosing intervals. The app, built on Baysient's iDose platform, aims to address traditionally high drug failure rates in Infliximab treatment and help physicians properly utilize therapeutic drug monitoring data. According to Dr. Diane Mould, Founder and CTO, the application can help caregivers find proper maintenance doses, dose intervals, and washout periods for individual patients.PR NewswireDigital Health Company Baysient Announces CDS/HCEI Software to Reduce Healthcare Cost in the Biosimilar MarketBaysient LLC announced the release of its iDose software technology platform version 1.0 for infliximab, presenting clinical validation results at Canadian Digestive Disease Week on February 28, 2020. A 12-month clinical study demonstrated the software's potential to reduce patient switching from lower-cost infliximab to more expensive biologics by 66%, which could generate healthcare savings of approximately $726,000 per 100 patients failing therapy. The company is currently conducting similar studies in nine countries across three continents involving over 300 patients, with additional Clinical Decision Support products in development for 25 other FDA-approved anti-inflammatory biologics.